The Rise Of Affordable Fertility Treatments

Béa Fertility has a plan to launch the first at-home fertility clinic, making insemination treatment affordable, accessible and bring up the potential success rates.

Fertility clinics and treatments are infamously tough to access. While one in seven couples in the UK faces infertility challenges, it is estimated that less than five per cent of these people can get access to treatment. Because of cuts to funding and stringent rules on who can be treated, just 35 per cent of IVF is funded by the NHS, and increasingly the field is dominated by private fertility clinics, which has made it difficult for many people to afford treatment. For gay or lesbian couples, who have the added cost of acquiring donor eggs and/or sperm for artificial insemination, the problem is even worse. Insemination at home seems to be the obvious answer, but with few resources available to support and guide people trying to do this, it can easily become overwhelming for those who want the treatments offered by fertility clinics, at home.


One British startup wants to change that and create a new option, which combines the home and the fertility clinic. Béa Fertility – which was co-founded by David O’Rourke, George Thomas and Tess Cosad – are launching the first at-home fertility treatment after netting $1m (£700,000) in pre-seed funding in April. Their aim is to make fertility treatments affordable and accessible to those locked out of the system. Béa Fertility’s kits, will be delivered straight to your door, for you to perform home insemination easily and effectively. These affordable kits will be a comprehensive treatment and include pregnancy tests, fertility tests and sperm donation pots, alongside their main product: an intracervical insemination (ICI) device. This is an applicator used to place a silicone cap (provided) filled with sperm onto the cervix, where it stays for four to six hours.


“I’m a clinical embryologist, so I worked on Harley Street for a long time,” explains David. “And a tiny amount of people got the opportunity to sit in front of me. That was something I could only do for so long before I didn’t feel comfortable with it anymore.” Tackling that issue led him to work on an home insemination device to “crack open” access. It was after three years of stringent research and over ninety prototypes that David connected with Tess, a marketing specialist with experience working with several technology companies. “I knew I was looking for something else,” Tess says. “And working on something that drives [fertility] access fits right in my wheelhouse.”


Béa Fertility’s technology, intracervical insemination (ICI), is a long-established conception strategy, but has been increasingly replaced by in-clinic options such as In Vitro Fertilisation (IVF) and Intrauterine Insemination (IUI). “A lot of papers were produced around ICI and IUI documenting very similar efficacy rates,” explains David. Béa expects the at home insemination kit to deliver the same kind of success rate as IUI – ten to twenty per cent on the first cycle – at a fifth of the cost of a single IUI treatment, which is typically around £1,500, making them a far more affordable fertility treatment option.


Fertility treatments are most effective after multiple rounds, but the high cost of IVF and IUI often makes that impossible for many. The lower cost of the Béa kit will make it a affordable fertility treatment for monthly use, thus bringing up the potential success rates – predictions are as high as 60 per cent after several months. By giving people the ability to perform insemination at home, effectively Béa hopes to give their customers more control over their treatment process than they would experience in a fertility clinic.


“If you look at a lot of the innovation in the fertility sector today, it’s very easy to innovate digitally,” explains Tess, citing the abundance of cycle-tracking apps, hormone testing and more that dominates the booming fertility-tech scene. “We’re going right to the centre of the problem.”


That hardware focus comes with challenges, such as stringent regulation for medical devices such as Béa’s, but Tess and David expect to get UK and EU medical clearance by the end of this year, allowing them to fully launch in 2022. As infertility rates have skyrocketed in recent decades, the Béa team is sure the issue isn’t going away. “The problem is only going in one direction,” Tess says. “We need more treatment options.”

This article was edited by Béa Fertility, read the original article by Andrew Kersley in full in Wired Magazine.

Disclaimer: Gender is experienced differently by all, particularly when it comes to our fertility. Our articles are written by a variety of authors, all of whom bring their experiences into their writing. Some articles will reflect these experiences more than others, and our goal is always to create content that represents all families.

Any general advice given by our care team or posted on our blog, website, or app is for informational purposes only and is not intended to replace or substitute for any medical advice, diagnosis, or treatment. Béa Fertility, the trading name for StepOne Fertility Ltd. makes no representations or warranties and expressly disclaims any and all liability concerning any treatment, action by, or effect on any person following the general information offered or provided within or through the blog, website, or app.